Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy

Mauricio Sarmiento(Pontificia Universidad Católica de Chile), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Isabel Sánchez‐Ortega(European Society for Blood and Marrow Transplantation), Isabel Pizarro(Pontificia Universidad Católica de Chile), Nicole Beffermann(Pontificia Universidad Católica de Chile), Rocío Parody(Institut Català d'Oncologia), Mauricio Ocqueteau(Pontificia Universidad Católica de Chile), Verónica Jara(Pontificia Universidad Católica de Chile), Pablo Bertín(Pontificia Universidad Católica de Chile), Mauricio Galleguillos(Pontificia Universidad Católica de Chile), Elizabeth Rivera(Pontificia Universidad Católica de Chile), C. Lorca(Pontificia Universidad Católica de Chile), Pablo Ramírez(Instituto Murciano de Investigación Biosanitaria), MQ. Salas(Institut Català d'Oncologia), Beatriz Patiño(Institut Català d'Oncologia)
Bone Marrow Transplantation
February 7, 2018
10.1038/s41409-018-0117-5
Cited by 52

Related Papers

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2015|740
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532